PR97960

KEFAR SAVA, Israel, Sept. 21, 2022 /PRNewswire=KYODO JBN/-

- Ivory Dentin Graft creates a new dentin category of graft substitutes for

repair and augmentation of bone defects.

    Developed by Ivory Graft Ltd.[]https://ivorygraft.com/, the Ivory Dentin

Graft(TM) is a new dentin graft. This graft material has been tailored for use

in dental procedures based on the advantages of autologous dentin grafts,

documented and proven in years of scientific research and publications. An

active organic matrix, Ivory Dentin Graft retains the natural form of the

sourced porcine dentin, as well as the protein matrix. Ivory Dentin Graft is CE

marked (according to MDR 2017/745).

    Ivory Dentin Graft is sourced from natural dentin, without additives.

Dentin's composition is very similar to bone, therefore its biological and

physicomechanical properties make it an ideal grafting material.

    This unique dentin graft substitute has been clinically proven to support

new hard tissue formation. A prospective, randomized, semi double-blinded with

blinded assessments clinical study was conducted. The study compared subjects

grafted with Ivory Dentin Graft (Investigational group) and subjects grafted

with a porcine cortico-cancellous heterologous bone mix (Comparator group) for

alveolar ridge preservation following tooth extraction. At 4 months

post-procedure – the study demonstrated Ivory Dentin Graft's efficacy results:

superior promoting of good interface between the host bone and graft material

(85% vs 40%), and 50% more increase of new bone formation (60.75% vs 42.81%

respectively). These two features are important for tissue regeneration and

integration, that follow tooth extraction and grafting, and facilitate

osteogenic activity.

    "We believe that Ivory Graft's patented technology for this new category of

dentin grafts has the potential to revolutionize dental graft substitutes and

clinical grafting materials in general" said Eyal Miller, CEO. "We look forward

to exhibiting and meeting with leading clinicians at the European Congress of

Osseointegration (EAO) in Geneva next week and invite you to visit our booth

(D47). Ivory Graft has shifted phase from R&D to commercialization, and

partnered with expert European commercial partners, to accelerate Ivory Dentin

Graft's presence in the EU. We are currently in the final phases of

establishing our Distributing Partners and Key Opinion Leaders' network, with

world leading professionals."

    About Ivory Graft [http://www.ivorygraft.com/]

    Established in 2013, Ivory Graft Ltd. is focused on developing,

manufacturing and marketing porcine dentin graft materials for the repair or

augmentation of bone defects. Ivory Graft has developed a naturally sourced,

bioresorbable dentin graft material with an active organic matrix. Ivory Dentin

Graft is CE marked, and the regulatory process for FDA clearance is underway.

Ivory Graft's plans for future products include orthopedic (spine) applications

as well as additional dental devices. Privately held, Ivory Graft was founded

and is funded by leading clinicians and industry leaders. Ivory Graft is

located in central Israel, within the innovative and thriving medical and

dental ecosystem.

    LinkedIn  [https://www.linkedin.com/company/ivory-graft-ltd/]

    Logo - https://mma.prnewswire.com/media/1901824/Ivory_Graft_Logo.jpg

    Source: Ivory Graft Ltd.